Transforming Hemophilia Treatment With Novel Rebalancing Agents: Clinical Studies and Practical Perspectives
While conventional prophylaxis with clotting factor concentrates (CFC) is the standard of care for hemophilia A and B, its challenges include frequent intravenous administration, factor level fluctuations, and potential inhibitor development. Rebalancing agents, including fitusiran (antithrombin-lowering small interfer...